Nantes, France – September 5, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the presentation of new analyzes on the phase 3 Atalante-1 trial of the immunotherapy Tedopi® in patients with of advanced non-small cell lung cancer, in secondary resistance after failure of checkpoint inhibitor treatments, at the 2022 ESMO (European Society for Medical Oncology) conference to be held in Paris from 9 to 13 september.
Alexis Vandier, CEO of OSE Immunotherapeutics, comments: “In patients in deadlock after failure of two therapeutic classes, in particular post-checkpoint inhibitors, Tedopi® shows in this phase 3 study an overall clinical benefit, integrating both efficacy and tolerance, compared to chemotherapy treatments. This new specific immunotherapy offers new prospects for management both as monotherapy and in combination. We will do everything possible to make this treatment available on as quickly as possible for these patients.”